Drug intelligence / Profile preview

IPB-106

Development stage: Preclinical
Lead developer: Interplay Bio
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

IPB-106 is a preclinical-stage targeted protein degrader (TPD) being developed by Interplay Bio for the treatment of pancreatic ductal adenocarcinoma (PDAC). Developed using the proprietary LigandPro platform, IPB-106 is designed to induce the degradation of an undisclosed m6A reader protein, referred to as 'Protein X.' This target is frequently overexpressed in PDAC tumor tissues and is involved in the regulation of multiple cancer-related genes, correlating with poor patient prognosis. By targeting this traditionally undruggable protein, IPB-106 aims to disrupt oncogenic signaling pathways and provide a new therapeutic option for pancreatic cancer patients.

Targets

CRL4-CRBN (Cereblon-based E3 ubiquitin ligase complex)m6A reader (m6A reader proteins)

Beyond the preview

Go deeper on IPB-106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IPB-106.

Explore the full profile